-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2023/11/23/US20230374027A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230374027A1
公开(公告)日：2023-11-23
申请号：US18361582
申请日：2023-07-28
Applicant: AbbVie Inc.
Inventor： Ayman Allian , Jayanthy Jayanth , Mohamed-Eslam F. Mohamed , Mathew M. Mulhern , Fredrik Lars Nordstrom , Ahmed A. Othman , Michael J. Rozema , Lakshmi Bhagavatula , Patrick J. Marroum , Peter T. Mayer , Ahmad Y. Sheikh , Thomas B. Borchardt , Ben Klünder , Heidi S. Camp , Robert J. Padley , Jeffrey W. Voss
IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/12 , A61K47/38
CPC classification number: C07D487/14 , A61K9/0053 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
-
公开(公告)号：US20150210708A1
公开(公告)日：2015-07-30
申请号：US14610119
申请日：2015-01-30
Applicant: AbbVie Inc.
Inventor： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael M. Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller
IPC: C07D487/14
CPC classification number: C07D487/14 , C07D498/14 , C07D513/14
Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Abstract translation: 本发明提供式（I）化合物的药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。
-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3,-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2025/05/22/US20250163071A1/abs.jpg.150x150.jpg)
公开(公告)号：US20250163071A1
公开(公告)日：2025-05-22
申请号：US19032963
申请日：2025-01-21
Applicant: AbbVie Inc.
Inventor： Ayman Allian , Jayanthy Jayanth , Mohamed-Eslam F. Mohamed , Mathew M. Mulhern , Fredrik Lars Nordstrom , Ahmed A. Othman , Michael J. Rozema , Lakshmi Bhagavatula , Patrick J. Marroum , Peter T. Mayer , Ahmad Y. Sheikh , Thomas B. Borchardt , Ben Klünder , Heidi S. Camp , Robert J. Padley , Jeffrey W. Voss
IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/02 , A61K47/12 , A61K47/38 , C07D487/04
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2024/01/11/US20240010656A1/abs.jpg.150x150.jpg)
公开(公告)号：US20240010656A1
公开(公告)日：2024-01-11
申请号：US18369272
申请日：2023-09-18
Applicant: AbbVie Inc.
Inventor： Ayman Allian , Jayanthy Jayanth , Mohamed-Eslam F. Mohamed , Mathew M. Mulhern , Fredrik Lars Nordstrom , Ahmed A. Othman , Michael J. Rozema , Lakshmi Bhagavatula , Patrick J. Marroum , Peter T. Mayer , Ahmad Y. Sheikh , Thomas B. Borchardt , Ben Klünder , Heidi S. Camp , Robert J. Padley , Jeffrey W. Voss
IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/12 , A61K47/38
CPC classification number: C07D487/14 , A61K9/0053 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
-
公开(公告)号：US09365579B2
公开(公告)日：2016-06-14
申请号：US14610119
申请日：2015-01-30
Applicant: AbbVie Inc.
Inventor： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael M. Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller
IPC: C07D487/14 , C07D498/14 , C07D513/14
CPC classification number: C07D487/14 , C07D498/14 , C07D513/14
Abstract: The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.
Abstract translation: 本发明提供式（I）化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫和肿瘤病症。
-
Patent Agency Ranking
公开(公告)号：US20160000936A1
公开(公告)日：2016-01-07
申请号：US14736256
申请日：2015-06-10
Applicant: AbbVie Inc.
Inventor： Carolyn Cuff , Melanie C. Ruzek , Jeffrey W. Voss
CPC classification number: A61K49/0008 , A61K2039/507 , C07K16/241 , C07K16/244 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/564 , G01N33/6863 , G01N33/6866 , G01N33/6869 , G01N2333/522 , G01N2333/525 , G01N2333/54 , G01N2800/102 , G01N2800/50 , G01N2800/52 , G01N2800/60 , G01N2800/7095
Abstract: The invention provides methods for predicting the efficacy of anti-TNF and anti-IL-17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level LIF, CXCL1, CXCL2, CXCL4, CXCL5, CXCL8, CXCL9, CXCL10, CCL2, CCL23, IL-1β, IL-1Ra, TNF, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IFNγ, CXCR1, CXCR4, CXCR5, GM-CSF, GM-CSFR, G-CSF, G-CSFR protein or nucleic acid, or a homolog, portion or derivative thereof markers in a sample derived from the subject.
Abstract translation: 本发明提供了通过确定LIF，CXCL1，CXCL2，CXCL4，CXCL5，CXCL8，CXCL9，CXCL5，CXCL8，CXCL9，CXCL5， CCL2，CCL23，IL-1和bgr，IL-1Ra，TNF，IL-6，IL-10，IL-17A，IL-17F，IL-21，IL-22，IFNγ，CXCR1，CXCR4，CXCR5， ，GM-CSFR，G-CSF，G-CSFR蛋白或核酸，或其衍生自受试者的样品中的同源物，部分或衍生物。
-
公开(公告)号：US20150118229A1
公开(公告)日：2015-04-30
申请号：US14523052
申请日：2014-10-24
Applicant: ABBVIE INC.
Inventor： Jeffrey W. Voss , Heidi S. Camp , Robert J. Padley
IPC: A61K31/4985 , A61K45/06
CPC classification number: A61K31/4985 , A61K31/167 , A61K31/192 , A61K31/198 , A61K31/4164 , A61K31/42 , A61K31/4353 , A61K31/4706 , A61K31/496 , A61K31/498 , A61K31/519 , A61K31/52 , A61K31/5415 , A61K31/573 , A61K31/575 , A61K31/606 , A61K31/616 , A61K31/655 , A61K38/13 , A61K45/06 , A61K2300/00
Abstract: The invention relates to the use of a JAK1 kinase-selective inhibitor that has minimal inhibitory activity towards Jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe Rheumatoid Arthritis) and/or bone loss, either alone or in combination with a DMARD (disease modifying anti-rheumatic drug), such as methotrexate. The invention also provides pharmaceutical composition, dosage formulation, administration route, and dosage schedule thereof.
Abstract translation: 本发明涉及对Jak2激酶具有最小抑制活性的JAK1激酶选择性抑制剂的用途，用于治疗诸如炎性疾病（例如中度至重度类风湿关节炎）和/或骨丢失的疾病，单独使用或 与DMARD（疾病改善抗风湿药物）组合，如甲氨蝶呤。 本发明还提供药物组合物，剂量制剂，给药途径和剂量方案。
-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2024/05/30/US20240174682A1/abs.jpg.150x150.jpg)
公开(公告)号：US20240174682A1
公开(公告)日：2024-05-30
申请号：US18530077
申请日：2023-12-05
Applicant: AbbVie Inc.
Inventor： Ayman Allian , Jayanthy Jayanth , Mohamed-Eslam F. Mohamed , Mathew M. Mulhern , Fredrik Lars Nordstrom , Ahmed A. Othman , Michael J. Rozema , Lakshmi Bhagavatula , Patrick J. Marroum , Peter T. Mayer , Ahmad Y. Sheikh , Thomas B. Borchardt , Ben Klünder , Heidi S. Camp , Robert J. Padley , Jeffrey W. Voss
IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/02 , A61K47/12 , A61K47/38 , C07D487/04
CPC classification number: C07D487/14 , A61K9/0053 , A61K31/4985 , A61K47/02 , A61K47/12 , A61K47/38 , C07D487/04 , C07B2200/13
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
-
![Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof](/abs-image/US/2024/05/28/US11993606B2/abs.jpg.150x150.jpg)
公开(公告)号：US11993606B2
公开(公告)日：2024-05-28
申请号：US18453085
申请日：2023-08-21
Applicant: AbbVie Inc.
Inventor： Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Aileen L. Pangan , In-Ho Song , Ben Klünder , Jeffrey W. Voss , Robert J. Padley , Heidi S. Camp
IPC: A61K31/4985 , A61K9/00 , A61K47/12 , A61K47/38 , C07D487/14
CPC classification number: C07D487/14 , A61K9/0053 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
-
![PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF](/abs-image/US/2023/12/14/US20230399333A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230399333A1
公开(公告)日：2023-12-14
申请号：US18453085
申请日：2023-08-21
Applicant: AbbVie Inc.
Inventor： Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Aileen L. Pangan , In-Ho Song , Ben Klünder , Jeffrey W. Voss , Robert J. Padley , Heidi S. Camp
IPC: C07D487/14 , A61K9/00 , A61K47/12 , A61K47/38 , A61K31/4985
CPC classification number: C07D487/14 , A61K9/0053 , A61K47/12 , A61K47/38 , A61K31/4985 , C07B2200/13
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.039 seconds)
